Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by LaserStock29on May 06, 2022 10:24pm
282 Views
Post# 34664006

RE:RE:RE:RE:RE:Theralase Hiring New IR Coordinator

RE:RE:RE:RE:RE:Theralase Hiring New IR CoordinatorI think Endocyte had exaclty $0 dollars of revenue.. was exiting phase 2 into phase 3 before Novartis paid 2.1b for their 'single asset' radionucleotide molecule. 

Im here for the big PPS run to $2 bucks+++ long before revenue even enters this conversation.

Please dont say we are gonna sit at .30 cents until we're making revenue on TLD-1433 

lol

Legit62 wrote: Clearly didnt mean revenue, obviously we are way away from any type of substantial revenue, i was thinking more of a partner coming on board with some financial support, i still believe we may see this before any BTD announced, and would bet we have been in talks all along with FDA, i would think Dr Vera has been highly involved in this


<< Previous
Bullboard Posts
Next >>